[The efficacy of lincomycin in tick-borne encephalitis].
Lincomycin was found to inhibit tick-borne encephalitis (TBE) virus. To test antiviral potential of this drug, a clinical trial was initiated entering TBE patients from known focuses of the disease (Novosibirsk, Kemerovo, Perm and Irkutsk Provinces). The drug was given to 23 patients with meningeal and meningoencephalitic TBE. A control group of 22 matched subjects received specific immunoglobulin. Resultant efficacy of lincomycin appeared not inferior to that of anti-TBE immunoglobulin. Lincomycin can be successfully introduced in the treatment of meningeal and meningoencephalitic TBE.
Votiakov
V I
VI
Mishaeva
N P
NP
Protas
I I
II
Ierusalimskiĭ
A P
AP
Shutov
A A
AA
Kovalenko
V N
VN
Kichkil'deev
N K
NK
Samoĭlova
T I
TI
Drakina
S A
SA
Zgirovskaia
A A
AA
D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004675:Encephalitis, Tick-Borne / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008034:Lincomycin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014586:USSR
D008034:Lincomycin
Ob éffektivnosti linkomitsina pri kleshevom éntsefalite.